DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Christian Hartmann - 1 Jean - 1 Luc Lagardere - 1 Alain Carpentier - 1 Carpentier - 1 Stephane Piat - 1 Emmanuel Macron - 1 Thomas Toepfer - 1
Top related locs:
Velizy Paris French Carmat United States Lagardere Taiwan Coblevo
Top related orgs:
REUTERS - 1 Rights - 1 Airbus - 1 PARIS - 1 Lagardere's Matra Defense - 1 Carmat - 1 Rx Securities - 1 FDA - 1

Search resuls for: "Piat"


3 mentions found


☆ Artificial heart maker Carmat's future seen in hands of core backers
  + stars: | 2023-09-29 | by ( Michal Aleksandrowicz Tim Hepher Laura Lenkiewicz | Michal Aleksandrowicz | Tim Hepher | ) www.reuters.com   time to read: +4 min
An artificial heart by French manufacturer Carmat is seen during an interview with Reuters in Velizy, near Paris, January 11, 2021. Sources said Carmat, which had 24 million euros cash at mid-year, was looking to raise a total of around 100 million. Airbus said this week it had invested 50 million euros in Carmat but did not address whether it would spend more. It most recently invested 10 million euros in March 2022. Matra Defense paid a dividend of 207 million euros to Airbus in 2022, filings show.
Persons: Christian Hartmann, Jean, Luc Lagardere, Alain Carpentier, Carpentier, Stephane Piat, Emmanuel Macron, Thomas Toepfer, Piat, Samir Devani, Carmat, Tim Hepher, Michal Aleksandrowicz, Laura Lenkiewicz, Stephanie Hamel, Josephine Mason, Elaine Hardcastle Organizations: Reuters, REUTERS, Rights, Airbus, PARIS, Lagardere's Matra Defense, Carmat, Rx Securities, FDA, Zurich University, Matra Defense, Thomson Locations: Velizy, Paris, French, Carmat, United States, Lagardere, Taiwan
☆ CARMAT says its Aeson artificial heart product will form part of French clinical study
  + stars: | 2023-01-04 | by ( ) www.reuters.com   time to read: 1 min
PARIS, Jan 4 (Reuters) - French healthcare and medical technology company CARMAT (ALCAR.PA) said on Wednesday that its Aeson artificial heart product would be implemented within the framework of a clinical study in France known as 'EFICAS'. "EFICAS is the largest study undertaken by CARMAT at this stage, and I am delighted that it will entirely take place in France, thus enabling our country's patients to benefit from our therapy. This is a crucial study, as it will eventually notably allow us to obtain Aeson’s reimbursement in France," said CARMAT chief executive Stéphane Piat in a statement. Reporting by Sudip Kar-Gupta; Editing by Christopher CushingOur Standards: The Thomson Reuters Trust Principles.
☆ RAPORT/ Neconformități la determinarea prețului proprietăților de stat și privatizări de terenuri aferente obiectivelor privatizate la prețuri mai mici de până la 26 ori comparativ cu valoarea de piaț
  + stars: | 2021-06-25 | by ( Mudrii Elena | ) www.zdg.md   time to read: +5 min
„În cazul a patru obiective, valoarea estimată prin metoda cheltuielilor a fost micșorată cu 23,7 mil. Totodată, pachetul de acțiuni a fost privatizat în cadrul unui singur concurs cu participarea doar a unui singur ofertant. aparține întreprinderii, însă în realitate a fost transmisă în gestiunea APP încă din anul 2011, conform unei hotărâri a Guvernului. Analizele de audit au atestat și privatizarea a trei terenuri aferente obiectivelor privatizate la prețuri de 3-26 ori mai mici comparativ cu valoarea de piață a acestora. lei și 21 obiective, fiind privatizate prin concursuri comerciale cu valoare de 436 mil.
Organizations: Agenția Proprietății, Autoritatea, Centrală Locations: Coblevo, Ucraina
0 next >>
Total: 3